Please assess the completion status of the following clinical trial:

Trial Title: Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stable, moderate to severe plaque psoriasis in at least three distinct plaque areas, each separated by at least a 2.5-cm band of normal skin. Study plaque areas, each covering a contiguous area up to 15 x 35 cm in size, should have a minimum plaque size of 2 cm2. All study plaque areas must be on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous sites).~* Fitzpatrick skin type I-VI.~* Ability to understand and sign the informed consent document.~Exclusion Criteria:~* Female subjects of childbearing potential who are pregnant, attempting to conceive, or nursing an infant.~* Subjects who have received PUVA or UVB light therapy or systemic antipsoriatic therapy within 4 weeks of study treatment (two weeks for methotrexate).~* Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin, or Vitamin D analogs) to the study plaque areas within 2 weeks of study treatment.~* Subjects who have received any photosensitizing or phototoxic drug within 4 weeks of study treatment.~* Subjects who have received any approved biologic drug therapy for psoriasis within 3 months or 5 half-lives of study treatment.~* Subjects who have participated in a clinical research study within 4 weeks of study treatment.~* Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.~* Subjects with clinical conditions that, in the opinion of the Principal Investigator, may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.

Based on this trial design, predict the completion outcome and termination type (if applicable).